关闭
 
读者在线:用户名 密码
首页 期刊简介 投稿须知 期刊目录 专家风采 编委会 特邀顾问 广告发行 联系我们 移动出版
  1. 1
  2. 2
  3. 3
  4. 4
  5. 5



刊物信息

期刊名称:药物分析杂志
主管单位:中国科学技术协会
主办单位:中国药学会
承办:中国食品药品检定研究院
主编:金少鸿
地址:北京天坛西里2号
邮政编码:100050
电话:010-67012819,67058427
电子邮箱:ywfx@nicpbp.org.cn
国际标准刊号:ISSN 0254-1793
国内统一刊号:CN 11-2224/R
邮发代号:2-237
 

访问统计
您是第  2 2 0 5 3 3 7 位浏览者
您当前的位置:首页 >> 正文

LC-MS/MS生物分析中试验样品再分析失败后的调查和解决方案

Investigation and resolution of incurred sample reanalysis failures in LC-MS/MS bioanalysis

分类号:
出版年·卷·期(页码):2016,36 (4):0-0
DOI: 10.16155/j.0254-1793.2017.01.01
-----摘要:-------------------------------------------------------------------------------------------

试验样品再分析(ISR)如今已普遍用于法规依从的生物分析实验室,是评估生物分析方法的重现性、可靠性和准确度的基本措施之一。虽然统计数据显示,LC-MS/MS生物分析中95%以上的ISR符合接受标准,然而失败时依然值得进行充分的科学调查与评估,以发现其根本原因。本文从稳定性问题、人为因素、样品处理过程、方法固有缺陷等方面对小分子化学药物的ISR失败原因进行分类分析,并举例讨论ISR影响因素及改进措施,列出ISR失败后需查根溯源,重测ISR,撰写调查报告并分享讨论等调查流程,并就如何降低ISR失败率提出法规依从,充分了解化合物特性,使用真实样品考察稳定性的解决方案,最后对其前景进行展望。

-----英文摘要:---------------------------------------------------------------------------------------

Incurred sample reanalysis(ISR), which is now widely applied in regulated bioanalytical laboratories, can serve as a measure of the reproducibility, robustness and accuracy of bioanalytical methods. Even with an average ISR success rate of 95% or higher and an increasing number of ISR tests being conducted in LC-MS/MS assays, more and more situations deserve scientific evaluation or investigation for the unmatched reassay results to reveal the cause.The purpose of this thesis is to classify the factors in ISR failure investigations for small molecule medicines the terms of instability of drug/metabolites, human error, sample processing and method error.Five case studies, were described where incurred sample reanalysis failure were encountered.The following approaches were listed, including cause identification, ISR reanalysis, document investigation and group discussion.Which could be taken to elucidate the failure.Meanwhile, the following remedial actions were proposed, including the regulatory compliance bioanalysis, thorough study of the analyte, and application of real samples in stability determination.Finally, the perspective of ISR in future was discussed.

-----参考文献:---------------------------------------------------------------------------------------
[1] FAST DM,KELLEY M,VISWANATHAN CT,et al.AAPS workshop on current topics in GLP bioanalysis:assay reproducibility for incurred samples-implications of Crystal City recommendations[J].AAPS J,2009,11(2):238
[2] LI WK,LIN H,FLARAKOS J,et al.Practical approaches to incurred sample LC-MS/MS reanalysis:confirming unexpected results[J].Anal Chem,2013,85(4):2405
[3] BANSAL S,ARNOLD M,GAROFOLO F.International harmonization of bioanalytical guidance[J].Bioanalysis,2010,2(4):685
[4] SAVOIE N,GAROFOLO F,VAN AMSTERDAM P,et al. White paper on recent issues in regulated bioanalysis & global harmonization of bioanalytical guidance[J].Bioanalysis,2010,2(12):1945
[5] VISWANATHAN CT.Incurred sample reanalysis:a global transformation[J].Bioanalysis,2011,3(23):2601
[6] 魏敏吉,李可欣.符合法规和指南要求的生物样本分析[J].药物分析杂志,2014,34(1):12 WEI MJ,LI KX.Bioanalysis performed according to regulations and guidelines[J].Chin J Pharm Anal,2014,34(1):12
[7] 李敏,史爱欣,李可欣,等.化学药物临床药动学试验样品再分析的一般要求及解读[J].中国新药杂志,2014,23(12):1378 LI M,SHI AX,LI KX,et al.General requirements for incurred sample reanalysis in clinical pharmacokinetic studies and the interpretation[J].Chin J New Drugs,2014,23(12):1378
[8] KELLEY M.Incurred sample reanalysis:it is just a matter of good scientific practice[J].Bioanalysis,2011,3(9):931
[9] BANSAL S.AAPS Bioanalytical Survey.Presented at:The AAPS Third Bioanalytical Workshop:Quantitative Bioanalytical Methods Validation and Implementation[R].Crystal City,VA,2006
[10] AAPS.Third Bioanalytical Workshop:Quantitative Bioanalytical Methods Validation and Implementation[R].Crystal City,VA, 2006
[11] TIMMERMAN P,LUEDTKE S,Van AMSTERDAM P,et al. Incurred sample reproducibility:views and recommendations by the European Bioanalysis Forum[J].Bioanalysis,2009,1(6):1049
[12] MENG M,REUSCHEL S,BENNETT P.Identifying trends and developing solutions for incurred sample reanalysis failure investigations in a bioanalytical CRO[J].Bioanalysis,2011,3(4):449
[13] TAN A,GAGNON-CARIGNAN S,LACHANCE S,et al.Beyond successful ISR:case-by-case investigations for unmatched reassay results when ISR passed[J].Bioanalysis,2011,3(9):1031
[14] ROCCI ML J,COLLINS E,WAGNER-CARUSO KE,et al. Investigation and resolution of incurred sample reanalysis failures:two case studies[J].Bioanalysis,2011,3(9):993
[15] FU Y,LI W,SMITH HT,et al.An investigation of incurred human urine sample reanalysis failure[J].Bioanalysis,2011,3(9):967
[16] YADAV M,SHRIVASTAV PS.Incurred sample reanalysis(ISR):a decisive tool in bioanalytical research[J].Bioanalysis,2011,3(9):1007
[17] LI WK,ZHANG J,TSE F.Handbook of LC-MS Bioanalysis:Best Practices,Experimental Protocols,and Regulations[M].New Jersey:Wiley,2013:47
[18] COTE C,LAHAIE M,LATOUR S,et al.Impact of methylation of acyl glucuronide metabolites on incurred sample reanalysis evaluation:ramiprilat case study[J].Bioanalysis,2011,3(9):951
[19] DICAIRE C,B RUB E R,DUMONT I,et al.Impact of oxcarbazepine sulphate metabolite on incurred sample reanalysis and quantification of oxcarbazepine[J].Bioanalysis,2011,3(9):973
[20] 张煊,闫东,高静,等.生物样品分析中的试验样品再分析研究进展[J].药物分析杂志,2015,35(3):383 ZHANG X,YAN D,GAO J,et al.Research progress of incurred sample reanalysis in bioanalysis[J].Chin J Pharm Anal,2015,35(3):383
[21] GAROFOLO F.How to manage having no incurred sample reanalysis evaluation failures[J].Bioanalysis,2011,3(9):935
[22] 陈笑燕,詹燕,钟大放.生物样品定量分析方法验证中试验样品再分析的意义和对策[J].中国药学杂志,2014,13(49):1176 CHEN XY,ZHAN Y,ZHONG DF.Significance and implementation strategy of incurred sample[J].Chin Pharm J,2014,13(49):1176
[23] Food and Drug Administration.Draft Guidance for Industry:Bioanalytical Method Validation[EB/OL].(2013-09-12)[2015-06-30].http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM368107.pdf
[24] 于敏,张双庆,李佐刚.生物样品中化学药物定量分析方法验证的进展与解读[J].药物分析杂志,2013,33(11):2019 YUM,ZHANG SQ,LI ZG.Progress and interpretation of quantitative analytical method validation of chemical medicines in biological samples[J].Chin J Pharm Anal,2013,33(11):2019
[25] JEMAL M,OUYANG Z,XIA YQ.Systematic LC-MS/MS bioanalytical method development that incorporates plasma phospholipids risk avoidance,usage of incurred sample and well thought-out chromatography[J].Biomed Chromatogr,2010,24(1):2
[26] GUPTA A,SINGHAL P,SHRIVASTAV PS,et al.Application of a validated ultra performance liquid chromatography-tandem mass spectrometry method for the quantification of darunavir in human plasma for a bioequivalence study in Indian subjects[J].J Chromatogr B,2011,879(24):2443
[27] B RUB ER,TAILLON MP,FURTADO M,et al.Impact of sample hemolysis on drug stability in regulated bioanalysis[J].Bioanalysis, 2011,3(18):2097
[28] 刘斌,张印兵,岑小波.生物分析方法验证在药物非临床安全性评价中的应用[J].中国药理学与毒理学杂志,2013,27(3):480 LIU B,ZHANG YB,CENG XB.The application of bioanalytical method validation in non-clinical drug safety evaluation[J].Chin J Pharmacol Toxicol,2013,27(3):480
[29] JAMES CA,HILL HM.Procedural elements involved in maintaining bioanalytical data integrity for good laboratory practices studies and regulated clinical studies[J].AAPS J,2007,9(2):E123
[30] HILL H.Developing trends in bioanalysis[J].Bioanalysis,2009,1(8):1359
[31] FREISLEBEN A,BRUDNY-KOPPEL M,MULDER H,et al. Blood stability testing:European Bioanalysis Forum view on current challenges for regulated bioanalysis[J].Bioanalysis,2011,3(12):1333
[32] Health Canada.Guidance to Industry:Conduct and Analysis of Bioavailability and Bioequivalence Studies-Part A:Oral Dosage Formulations Used for Systemic Effects[EB/OL].
[1992] [2015-06-24].http://www.hc-sc.gc.ca/dhp-mps/prodpharma/applicdemande/guide-ld/bio/bio-a-eng.php
[33] European Medicines Agency.Guideline on Bioanalytical Method Validation:Committee for Medicinal Products for Human Use[EB/OL].
[2009] [2015-07-04].http://www.ema.europa.eu/docs/enGB/documentlibrary/Scientificguideline/2011/08/WC500109686.pdf
[34] 钟大放,李高,刘昌孝.生物样品定量分析方法指导原则(草案)[J].药物研究与评价,2011,34(6):409 ZHONG DF,LI G,LIU CX.Guidance on bioanalysis:method validation and analysis of study samples(Draft)[J].Drug Eval Res, 2011,34(6):409

欢迎阅读《药物分析杂志》!您是该文第 1379位读者!

药物分析杂志 © 2009
地址:北京天坛西里2号
邮政编码:100050; 技术支持:010-60213898

电子邮件:ywfx@nicpbp.org.cn